GeneDx Holdings (WGS) Common Equity (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Common Equity data on file, last reported at $254.1 million in Q1 2026.

• Common Equity for Q1 2026 came in at $254.1 million, down 1.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $254.1 million (down 1.27% YoY), and the FY2025 annual result was $308.2 million, up 25.66% from the prior year.
• Common Equity fell to $254.1 million in Q1 2026 per WGS's latest filing, from $308.2 million in the prior quarter.
• Over five years, Common Equity peaked at $637.3 million in Q2 2022 and troughed at $194.0 million in Q2 2024.
• A 5-year average of $301.7 million and a median of $257.4 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2023: Common Equity jumped 212.49% in 2022, then tumbled 54.7% in 2023.
• A 5-year view of Common Equity shows it stood at $253.7 million in 2022, then declined by 10.13% to $228.0 million in 2023, then gained by 7.56% to $245.2 million in 2024, then increased by 25.66% to $308.2 million in 2025, then retreated by 17.54% to $254.1 million in 2026.
• Business Quant data shows WGS's Common Equity at $254.1 million in Q1 2026, $308.2 million in Q4 2025, and $292.3 million in Q3 2025.